FDA places clinical hold on Beam's BEAM-201 IND for T-ALL/T-LL

Beam Therapeutics Inc.

FDA clinical hold on BEAM-201 IND for relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.
Beam informed via FDA email on July 29, 2022; IND submitted end of June.
BEAM-201 is an anti-CD7, multiplex-edited allogeneic CAR-T candidate.
FDA to provide official clinical hold letter within 30 days; Beam plans updates after discussions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.